Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- July 19, 2016
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Antihypertensive Agents (MeSH)
- Benzimidazoles (MeSH)
- Biphenyl Compounds (MeSH)
- Humans (MeSH)
- Hydrochlorothiazide (MeSH)
- Hypertension (MeSH)
- Rosuvastatin Calcium (MeSH)
- Tetrazoles (MeSH)
published in
- ACP journal club Journal